Compare Becton Dickinson and Co (BDX) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Upstart Holdings Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Upstart Holdings Inc trades at $31.87 (market cap $3.04B). The key difference: Becton Dickinson and Co is far larger — about 13.7× Upstart Holdings Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| BDX | UPST | |
|---|---|---|
Market Cap | $41.51B | $3.04B |
Sector | Health | Financials |
52-Week High | $185.39 | $84.13 |
52-Week Low | $135.49 | $24.22 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
UPST trades at $31.46, down 3.91% on the day, reflecting recent volatility amid mixed earnings. The stock shows a bearish technical trend with support near $29, while fundamentals highlight a return to profitability in 2025 with $1.02B revenue and $53.60M net income. Recent news emphasizes AI lending growth and a key $600M funding deal with Neuberger Berman, though margin pressures persist.
The outlook hinges on execution of AI-driven lending expansion and funding stability, with a consensus price target of $42.00 suggesting 33% upside. Risks include earnings volatility, high debt levels, and competitive fintech pressures. Analyst sentiment is balanced with 45% buy ratings, but investors await Q2 2026 results on August 4 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
